Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai, Takeda Report Losses Due to Acquisitions; Daiichi Sankyo Reports Earnings Lower Because Of NHI Drug Pricing

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Top Japanese pharmaceutical manufacturers July 31 reported mixed earnings results for their latest reporting periods, reflecting the costs of acquisitions and reductions in Japan's national health insurance drug pricing

You may also be interested in...



Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion

Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion

Future Of ESAs In Oncology Uncertain After Takeda Stops Development Of Hematide For CIA

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel